Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Circulating endocannabinoids and female sexual arousal

EF 2009-10

Résumé
The understanding of the physiological mechanisms underlying female sexual functioning is still in its infancy, especially compared to what is known about male sexual physiology. This knowledge deficit is manifest in the fact that there are various U.S. Food and Drug Administration (FDA) approved treatments for male sexual dysfunctions, but only one FDA approved treatment for female sexual dysfunctions, the EROS clitoral therapy device, which is not a pharmacological agent. Given the high prevalence rate of female sexual dysfunctions at approximately 40% and the various psychological factors such as mood and self-esteem impacted by these difficulties, better treatment and thus increased knowledge regarding female sexual functioning are imperative. A promising way to achieve both of these goals is to study the endocannabinoid system, which consists of cannabinoid receptors, their endogenous ligands, termed endocannabinoids, and the enzymes involved in their synthesis and metabolism. There is now a growing body of animal and human research pointing to this system's potential role in female sexual functioning, but past human research has been restricted to collecting self-report data with exogenous cannabinoids, which cannot reveal whether the endocannabinoid system actually plays a physiological role in female sexual functioning. The purpose of this study is to address this issue by being the first to collect physiological data on endocannabinoid and sexual arousal levels in women. If a relationship is found between these two variables, it suggests the possibility of developing female sexual arousal disorder treatments that would work through pharmacological manipulation of the endocannabinoid system.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
202549
Name
Chang Sabrina C
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Circulating endocannabinoids and female sexual arousal
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
2-Arachidonylglycerol (2-Ag); Anandamide (Aea); Endocannabinoid System; Female Sexual Arousal; Female Sexual Functioning; Phlebotomy; Sexual Dysfunction Treatment; Vaginal Photoplethysmography
Abstract
The understanding of the physiological mechanisms underlying female sexual functioning is still in its infancy, especially compared to what is known about male sexual physiology. This knowledge deficit is manifest in the fact that there are various U.S. Food and Drug Administration (FDA) approved treatments for male sexual dysfunctions, but only one FDA approved treatment for female sexual dysfunctions, the EROS clitoral therapy device, which is not a pharmacological agent. Given the high prevalence rate of female sexual dysfunctions at approximately 40% and the various psychological factors such as mood and self-esteem impacted by these difficulties, better treatment and thus increased knowledge regarding female sexual functioning are imperative. A promising way to achieve both of these goals is to study the endocannabinoid system, which consists of cannabinoid receptors, their endogenous ligands, termed endocannabinoids, and the enzymes involved in their synthesis and metabolism. There is now a growing body of animal and human research pointing to this system's potential role in female sexual functioning, but past human research has been restricted to collecting self-report data with exogenous cannabinoids, which cannot reveal whether the endocannabinoid system actually plays a physiological role in female sexual functioning. The purpose of this study is to address this issue by being the first to collect physiological data on endocannabinoid and sexual arousal levels in women. If a relationship is found between these two variables, it suggests the possibility of developing female sexual arousal disorder treatments that would work through pharmacological manipulation of the endocannabinoid system.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chang, Sabrina C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~